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Available online 29 June 2016The burden of cardiovascular disease (CVD) among minority and low-income populations is well documented.
This study aimed to assess the impact of patient activation and shared decision-making (SDM) on medication
use through theOfﬁce-Guidelines Applied to Practice (Ofﬁce-GAP) intervention in Federally QualiﬁedHealthcare
Centers (FQHCs).
Patients (243) with diabetes and CHD participated in Ofﬁce-GAP between October 2010 and March 2014. Two-
site (FQHCs) intervention/control design. Ofﬁce-GAP integrates health literacy, communication skills education
for patients and physicians, decision support tools, and SDM into routine care.Mainmeasures: 1) implementation
rates, 2) medication use at baseline, 3, 6, and 12months, and 3) predictors of medication use. Logistic regression
with propensity scoring assessed impact on medication use. Intervention arm had 120 and control arm had 123
patients.We found that program elementswere consistently used. Compared to control, the Ofﬁce-GAP program
signiﬁcantly improved medications use from baseline: ACEIs or ARBs at 3 months (OR 1.88, 95% CI = 1.07; 3.30,
p b 0.03), 6 months (OR 2.68, 95% CI = 1.58;4.54; p b 0.01); statin at 3 months (OR 2.00, 95% CI = 0.1.22; 3.27;
p b 0.05), 6 months (OR 3.05, 95% CI = 1.72; 5.43; p b 0.01), Aspirin and/or clopidogrel at 3 months OR 1.59, 95%
CI = 1.02, 2.48; p b 0.05), 6 months (OR 3.67, 95% CI = 1.67; 8.08; p b 0.01). Global medication adherence was
predicted only by Ofﬁce-GAP intervention presence and hypertension.
Ofﬁce-GAP resulted in increased use of guideline-based medications for secondary CVD prevention in under-
served populations. The Ofﬁce-GAP program could serve as a model for implementing guideline-based care for
other chronic diseases.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Secondary prevention of heart disease
Guidelines based care in outpatient settings
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Shared decision-making
Medication adherence1. Introduction
Disparities in cardiovascular health remain one of the most serious
public health problems in the US today (Lillie-Blanton et al., 2004;
Mensah, 2005). African-Americans, low-income and minority patients,
especially those with diabetes suffer a disproportionate burden of car-
diovascular diseases (CVD) morbidity and mortality (Wong et al.,
2002). These differentials in CVD outcomes are thought to be partially
attributable to disparities in CVD prevention and treatment and include
barriers of literacy and poverty that obstruct access to beneﬁts of sec-
ondary prevention. Anti-platelet agents, angiotensin-converting en-
zymes inhibitors (ACEIs), beta-blockers, and lipid-lowering agentsClinical Center Building, East
. This is an open access article underhave signiﬁcant morbidity and mortality beneﬁts for prevention of
CVD, but these agents are not optimally used (Chan et al., 2010). In gen-
eral, 20–50% of patients are medication non-adherent (DiMatteo et al.,
2002). Approximately 21–42% of patients with diabetes mellitus (DM)
are medication non-adherent (Cramer, 2004; Kim et al., 2010). The
lost opportunity for effective therapies to improve health is staggering
(Bosworth et al., 2011; Ho et al., 2006). Medication non-adherence un-
dermines treatment effectiveness resulting in poor diabetic and blood
pressure (BP) control, and increasing hospitalization, mortality, and
cost to the US healthcare system (Salas et al., 2009; Sokol et al., 2005).
The concept of medication adherence is complex and multifaceted and
needs to be considered within the context of patient, provider and sys-
tem issues (Rolley et al., 2008).
Translating practice guidelines into clinical practice has proved very
difﬁcult and challenging, even when the guidelines are well accepted
(Davis & Taylor-Vaisey, 1997). Behavioral change interventions have
been shown to be effective in outpatient settings (Koertge et al., 2003;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathway toward better quality health care and improved health out-
comes (Carman et al., 2013). Physician and patient interventions de-
signed in tandem to support the therapeutic partnership from both
perspectives have been advocated but infrequently implemented
(Roter & Larson, 2001). Only a few studies have simultaneously inter-
venedwith both patients and providers and objectivelymeasured inter-
vention effects on health outcomes (Grifﬁn et al., 2004). ‘Patient
activation’ describes skills and conﬁdence that equip patients to become
actively engaged in their healthcare (Hibbard et al., 2013). Some
patient-activation interventions designed to improve patient-
physician communication have been tested in patientswith chronic dis-
eases, but relatively few have used targeted strategies, and focused on
ethnic minorities and low socio-economic populations (Cooper et al.,
2011). In addition, patient pre-visit coaching has been shown to im-
prove patients' communication with their physicians and health out-
comes. (Kaplan et al., 1989). A recent Cochrane review of decision aids
(DAs) found high-quality evidence that DAs compared to usual care im-
prove people's knowledge regarding options, reduce their decisional
conﬂict and stimulate people to take amore active role in decisionmak-
ing (Stacey et al., 2014).
Our study addresses the need formore research on the use of shared
decision-making (SDM) and DAs, the translation of evidence-based de-
cision support interventions and guidelines-based care into practice.
We focus especially on community outpatient settings that serve mi-
nority low-income populations (Elwyn et al., 2013; Stacey et al.,
2014). We previously developed an integrated SDM intervention
(Holmes-Rovner et al., 2011) based on our research in patient and pro-
vider communication skills training (F. Dwamena et al., 2012; Smith
et al., 2000) and provision of problem-speciﬁc decision support tools
(DST) (Dwamena et al., 2008; Holmes-Rovner et al., 2000). In our
prior research, primary care physicians participated in a communication
and SDM skill training for patients with stable coronary artery disease
(CAD) going for stress test (Kelly-Blake et al., 2015). In the present
study, we used our intervention to encourage SDM in guidelines-
based medication use among patients with either diabetes or coronary
heart disease (CHD) or both, receiving care in Federally Qualiﬁed Health
Centers (FQHCs). TheOfﬁce-GAP Program(Fig. 1) is based on theHealth
Literacy Care Model (HLCM) (Koh et al., 2013) and the Relational
Coordination Model (Gittell, 2006). The HLCM is a systems approach
to improving patients' engagement in care. Relational coordination
refers to the quality of communication that strengthens interpersonalFig. 1. Ofﬁce-GAP intervention in Federally Qualiﬁed Healthcare Centers. GAP: Guidelines App
making CHD: coronary heart disease F/U: follow up.relationships (Gittell, 2006; Havens et al., 2010). This is fundamental
to collaborative goal setting that both patients and providers will em-
brace. The objectives of the Ofﬁce-GAP Program evaluation were to de-
termine: 1) feasibility of the Ofﬁce-GAP program among patients with
DM, CHD or both in two FQHCs in Michigan; 2) the impact on a) use
of guidelines-based medication for CHD prevention and b) the predic-
tors of medication use in FQHCs.
2. Methods
2.1. Study design and setting
A quasi-experimental design study, over 6 months, with 12-month
follow-up in 2 FQHCs in mid-MI. Centers were assigned to either inter-
vention or control by the toss of a coin. Patients were recruited fromOc-
tober 2010 to March 2014, using patient International Classiﬁcation of
Diseases (ICD)-9 Code. At patient visits where either DM or CHD or
both were on the problem list, practice staff informed patients about
the study and directed them to the research assistant (RA) for more in-
formation. Interested patients were scheduled for an Ofﬁce-GAP pro-
gram group visit.
2.1.1. Inclusion criteria
Adults aged 18 or older, who could provide informed consent. Pa-
tients with a diagnosis of DM, CHD or both.
2.1.2. Exclusion criteria
Cognitive impairment, dementia and psychosis as determined by
ICD-9 codes. Interpreters were used for non-English speaking patients.
Study participants received $30 reimbursement for transportation and
parking. The Michigan State University (MSU) Institutional Review
Board (IRB) approved the study.
All providers at both FQHC facilities (6 doctors, 3 nurse-practitioners
(NP)), 18 staff (Medical Assistants, Administrators, Receptionists, Social
Workers), and 243 patients participated in this pilot study. All partici-
pants signed an informed consent.
2.2. Interventions
The Ofﬁce-GAP tools were grounded in Guidelines of the American
Heart Association/American College of Cardiology Foundation (AHA/
ACCF) on secondary prevention of heart disease (Smith et al., 2011)lied to Practice PTC: patient-centered method of communication SDM: shared decision-
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betes, 2010). The process, developed previously, (Holmes-Rovner
et al., 2011) consisted of three Ofﬁce-GAP components: 1) physician
and practice staff training; 2) patient group visit; and 3) use of the
Ofﬁce-GAP checklist tool during follow-up provider visits. The checklist
tool, (Supplementary Table A) aided SDM and communication between
patient and provider. The checklist was stimulated by the Ofﬁce-GAP
hospital intervention in CAD by Eagle et al. (Mehta et al., 2002). It was
adapted for primary care by a teammember who is expert in DA devel-
opment (MHR), with attention to plain language (Holmes-Rovner et al.,
2005). Components were scripted and monitored to maintain study ﬁ-
delity as shown in Fig. 1. (Ofﬁce-GAP Intervention).
2.3. Physician and practice staff communication skills intervention
The physician communication intervention was a 90-min training
offered at 4 different times to accommodate staff schedules. Training in-
cluded a review of CHD secondary prevention guidelines and communi-
cation skills. Discussion of steps in the Patient-Centered Care Method of
Communication (PTC) (Smith et al., 2000), SDM and goal setting, was
led by PI (AO) and study team. The communication skills training goal
was to increase patient engagement, activation, goal setting and em-
powerment. The intervention focused on strong provider-patient rela-
tionships as described in the HLCM (Koh et al., 2013) and Relational
Coordination Model (Gittell, 2006). The research team, providers and
practice staff identiﬁed possible opportunities and pitfalls of the study
and discussed the best strategy for implementing the Ofﬁce-GAP tools
in the practice. Role-plays were conducted to model ofﬁce visit skills.
The training section was evaluated by surveying all participants at the
end of the training.
2.4. Patient intervention
Patients attended one group visit to learn SDM, communication
skills and reviewed DSTs similar to the skills and DSTs reviewed during
physician intervention.We deﬁne DST to include the Ofﬁce-GAP check-
list tool and DAs to support patient decision-making about CHD.
2.5. Group visit
The group visits (90–120min/visit) included four to six patients, and
were conducted by the RA and PI (AO). The group visit didactic content
included: 1) introduction to CHD and lifestyle changes, 2) secondary
prevention and living with CHD, 3) purpose and side effects of cardiac
medications. The ADA/ACP Booklet “Living with Diabetes” was
reviewed to set goals with diabetic patients. The program focused on
patient communication skills related to engagement, SDM, activation
and empowerment consistent to the provider intervention skills
(Dwamena et al., 2009; Roter, 1977).
2.6. Clinic visit
The Ofﬁce-GAP checklist was used to stimulate SDM, aid communi-
cation and impact the process of care by providing a systematic list of
evidence-based medications and interventions for patient and provider
to review together. The Ofﬁce-GAP checklist was the core SDM tool. It
was completed in real time by the physician and patient at two separate
ofﬁce visits (at 3 and 6 months). For each guideline-based item in the
list, the physician discussedwith the patient and checked,Yes (if patient
was on the medication or lifestyle activity), or No or Does not Apply to
me because… (ineligible for the medication, had a contraindication, or
unwillingness due to side effect concerns). The Ofﬁce-GAP checklist
also stated the next follow-up details. At the end of the visit the physi-
cian and patient signed the checklist form to conﬁrm that both of
them have discussed all the items. A copy of the checklist went to the
medical record and a copy was given to the patient.3. Measures
3.1. Intervention feasibility
Evaluation of tool utilization rates by providers, ofﬁce staff and pa-
tients. Patient measures included attendance at group visits and follow
up appointments. Physician measures included Ofﬁce-GAP tool utiliza-
tion rate as documented in the medical record (presence of the Ofﬁce-
GAP checklist signed byboth the provider and patient during each visit).
3.2. Medication use
Rates of using aspirin, beta-blocker, ACEI or ARBs, and cholesterol
treatment were obtained at baseline, 3, 6 and 12 months as primary
endpoints. The medication use measure is fundamentally a measure of
both physicians' prescribing and patients' ﬁlling the prescription. Med-
ication use was assessed by self-report at each visit and veriﬁed by pa-
tients bringing in all active medications. Only medications both
prescribed by the physician and obtained by the patient were included
in the analysis.
4. Data collection
Datawere collected from survey forms completed bypatients during
the group visit and ofﬁce visits. Chart abstractions were performed by
trained RAs according to a predeﬁned standardized data collection
sheet. Patient race was self-reported. The project ﬁeld manager contin-
ued to sample each reviewer's charts to maintain quality control. Reli-
ability ≥98% was maintained throughout.
5. Statistical analysis
t-Tests and chi-square tests were performed to examine differences
in baseline characteristics between the Ofﬁce-GAP intervention and the
control groups. Because of the longitudinal nature of the study, correlat-
ed data analyses using a generalized estimating equations (GEE) model
(Liang, 1986) were conducted to describe the proﬁle of medication use
across time, taking into account potential predictors. The model was
used to examine change from baseline in the proportion of eligible pa-
tients using aspirin and/or clopidogrel, angiotensin converting enzyme
inhibitors or angiotensin receptor blockers (ACEIs or ARBs), beta-
blockers and statins at 3 months, 6 months and 12 months, both for
the control and the intervention groups. Only medication eligible pa-
tients were included in the analysis for speciﬁc adherence, resulting in
different numbers of patients in each model (Medication eligibility
criteria: Supplementary Table B). Extending our statistical analysis for
medication use, we created a global medication adherence measure
based on the following algorithm: a variable that equals to the adher-
ence for ACEI if the personwas eligible for ACEI, else equals to the adher-
ence for aspirin; else equals to the adherence for statin; and else equals
the adherence for beta-blocker. In these analyses, the basic model im-
posed no linear structure of the time effects on the log-odds of medica-
tion use, rather treated time as a categorical variable. Hence the
intervention effects (Ofﬁce-GAP versus Control)were assessed using in-
teractions between the intervention group indicator and time.
Analysis was conducted using a balancing strategy based on the pro-
pensity score-PS method (Austin, 2011). The propensity score (proba-
bility of being on the Ofﬁce-GAP arm) was estimated using a logistic
regression model with potential confounders. We controlled for
patient's age, race, immigration status, gender, Body Mass Index
(BMI), smoking status, depression, primary insurance, burden of disease
(Charlson Index) and cardiologist visit. A sensitivity analysis based on
three PS adjustment methods was conducted; i) treating the PS as co-
variate in a covariance model, ii) stratifying the patients in quintiles of
PS, and iii) weighing patients by 1/PS for the GAP arm and 1/[1-PS] for
the control arm, in the longitudinal data analyses. Because all these
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generated from the inverse PS weight approach are reported. Finally,
longitudinal data analyses were conducted to determine the predictors
of medication use. A p-value of b0.05 is considered statistically signiﬁ-
cant in all analyses. All analyses were performed using SAS version 9.3
(SAS Institute).
6. Results
6.1. Patient characteristics
Of the 464 eligible patients, 317 patients consented to participate in
the program. Reasons for non-participation included, refusal to partici-
pate, did not show up for the group visit, inability to be contacted for
scheduling for group visit because their phoneswere disconnected. Sev-
enty-six patients were excluded (Olomu et al., 2016). Average age was
55.0 (SD 10.95) years, with BMI of 32.39 (SD 8.51). Approximately,
57% were females. Blacks and Whites were equal in number (38.2%);
Asian 13%; Hispanic 8.4% and 2% patients were from other races. 41.2%
had Medicaid, followed by Ingham Health Plan (40%); Medicare 25.2%
and others 14.7%. (Ingham Health Plan is a local county-based public
plan that covers ofﬁce visits and limited medication coverage.) There
were 88.8% patients with a history of DM, 74.9% with HTN, 57.6% withTable 1
Table of demographics for the intervention and control groups in Federally Qualiﬁed
Healthcare Centers.
Intervention
(n = 120)
Control (n =
123)
p-Value
Mean SD Mean SD
Age (years) 56.15 10.17 53.84 11.59 0.1049
BMI 32.60 8.57 32.18 8.49 0.7140
N % N %
Gender 120 123 0.8678
Males 52 43.33 52 42.28
Females 68 56.67 71 57.72
Race 117 121 b0.0001
White 40 34.19 51 42.15
Black 60 51.28 31 25.62
Asian 3 2.56 28 23.14
Hispanic 12 10.26 8 6.61
Others 2 1.71 3 2.48
Smokers 119 123 0.1611
Smokers 47 39.50 38 30.89
Non-smokers 72 60.50 85 69.11
Immigrant 111 120 b0.0001
Non-immigrant 102 91.89 70 58.33
Immigrant 9 8.11 50 41.67
Insurance (multiple-choice) 117 121
Medicaid 40 34.19 58 47.93 0.0312
Medicare 36 30.77 24 19.83 0.0521
Ingham Health Plan 50 42.74 45 37.19 0.3825
Others 10 8.55 25 20.66 0.0078
PMH (multiple-choice) 120 123
Hypertension 95 79.17 87 70.73 0.1295
High cholesterol 74 61.67 66 53.66 0.2066
Depression 58 48.33 37 30.08 0.0036
Asthma 15 12.50 12 9.76 0.4962
Stroke 8 6.67 9 7.32 0.8425
Congestive heart failure 8 6.67 7 5.69 0.7520
Cancer 14 11.67 10 8.13 0.3556
PVD 7 5.83 10 8.13 0.4828
CAD 24 20.00 15 12.20 0.0975
Charlson Index (CI) 120 122 0.1130
Mildly ill (1 ≤ CI ≤ 2) 25 20.83 39 31.97
Moderately ill (3 ≤ CI ≤ 4) 64 53.33 60 49.18
Severely ill (5 ≤ CI) 31 25.83 23 18.85
Diabetes 119 122 0.1735
With diabetes 109 91.60 105 86.07
Bold data indicates signiﬁcant at (P 0.05) values.Depression, and 16% with CHD. Approximately 73.6% of the patients
were moderately to severely ill based on Charlson Index score indicat-
ing substantial risk ofmortalitywithin the next 10 years for a typical pa-
tient (Charlson et al., 1987) and 35.1% were current smokers.
Table 1 show the baseline characteristics of the 243patients enrolled
in intervention and control arms. Therewere no statistical differences in
demographic and clinical characteristic between the intervention and
control arms except for race, immigrant status, type of insurance and
prevalence of depression.
6.2. Intervention feasibility and program ﬁdelity
All providers and staff attended the 90-min physician training.
Among the 243 patients who attended the ﬁrst 90-min group visits,
87.1% completed their ﬁrst Ofﬁce-GAP provider visit in the intervention
arm and similarly 89.3% completed this visit in the control arm; 81.9%
completed their second (ﬁnal) visit in the intervention arm, and 88.4%
did in the control arm. The Ofﬁce-GAP tool was found completed in
the medical record 98.7% of the time.
6.3. Medication use and predictors of medication use
Table 2 demonstrates the change from baseline for eachmedication,
and show that use of each medication improved in the intervention
group. We compare this to the control group and present a ratio of the
OR (as labeled in the table) to show that the intervention is superior
to the control. ACEIs or ARBs improved at 3 months (OR 1.82, 95%
CI = 1.07; 3.10. p b 0.03) and 6 months (OR 2.10, 95% CI = 1.32; 3.33,
p b 0.01). Statin use improved at 3 months (OR 2.00, 95% CI = 1.22;
3.27, p b 0.01) and 6months (OR 3.05, 95% CI= 1.72; 5.43 p b 0.01). As-
pirin and/or clopidogrel improved at 3months (OR 1.59, 95% CI= 1.02;
2.48, p b 0.03), 6 months (OR 3.67, 95% CI = 1.67; 8.08, p b 0.01), and
12 months (OR 2.64, 95% CI = 1.36; 5.10, p b 0.01). In the control arm,
only aspirin and/or Plavix use was signiﬁcant at 12 months (OR 1.31,
95% CI = 1.00; 1.73, p = 0.05). Compared to the control, theTable 2
Adjusted Odds Ratios, [95% CI], and p-values for medication use at follow-up visits com-
pared to baseline.
Intervention
(Ofﬁce-GAP)
Control Ratio of ORs:
Ofﬁce-GAP/control
ACEIa/ARBb use
3 months 1.82† [1.07, 3.10] 0.97 [0.82, 1.15] 1.88† [1.07, 3.30]
6 months 2.10⁎ [1.32, 3.33] 0.78 [0.61, 1.01] 2.68⁎ [1.58, 4.54]
12 months 1.38 [0.30, 2.10] 1.10 [0.23, 1.65] 1.25 [0.69, 2.26]
Statin use
3 months 2.00⁎ [1.22, 3.27] 1.14 [0.87, 1.52] 1.75 [0.99, 3.08]
6 months 3.05⁎ [1.72, 5.43] 1.16 [0.76, 1.75] 2.64⁎ [1.30, 5.38]
12 months 1.69 [0.95, 3.02] 1.26 [0.76, 2.09] 1.35 [0.62, 2.91]
Aspirin use
3 months 1.59† [1.02, 2.48] 1.07 [0.95, 1.20] 1.50 [0.95, 2.37]
6 months 3.67⁎ [1.67, 8.08] 1.07 [0.95, 1.20] 3.44⁎ [1.40, 7.65]
12 months 2.64⁎ [1.36, 5.10] 1.31 [1.00, 1.73] 2.01 [0.98, 4.11]
Beta-blocker use
3 months 1.48 [0.86, 2.53] 1.22 [0.92, 1.61] 1.21 [0.66, 2.22]
6 months 1.28 [0.79, 2.07] 1.14 [0.74, 1.73] 1.12 [0.59, 2.13]
12 months 1.34 [0.80, 2.24] 1.20 [0.69, 2.09] 1.11 [0.53, 2.36]
Global medication adherence
3 months 1.73† [1.04, 2.87] 0.97 [0.84, 1.11] 1.79† [1.06, 3.03]
6 months 1.97⁎ [1.26, 3.06] 0.81 [0.66, 1.00] 2.43⁎ [1.49, 3.97]
12 months 1.35 [0.90, 2.02] 1.08 [0.77, 1.52] 1.25 [0.74, 2.11]
Adjusted for hypertension, diabetes mellitus, and variables in the propensity score.
⁎ p-Value b 0.01.
† p-Value b 0.05.
a ACEI: angiotensin converting enzyme inhibitor.
b ARB: angiotensin receptor blocker.
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over time: ACEIs or ARBs at 3 months (OR 1.88, 95% CI = 1.07; 3.30,
p b 0.03), 6 months (OR 2.68, 95% CI = 1.58; 4.54; p b 0.01); statin at
3 months (OR 1.75, 95% CI = 0.99; 3.08; p b 0.05), 6 months (OR 2.64,
95% CI = 1.30; 5.38; p b 0.01), Aspirin and/or clopidogrel at 6 months
(OR 3.44, 95% CI = 1.40; 7.65; p b 0.01). There was no change in the
use of beta-blockers in either the intervention or the control arm
(Supplementary Table C). The rate of medication adherence improved
by the Ofﬁce-GAP intervention is reﬂective of improvement in the
physician's prescribing behavior as shown by increase in the rate of
medication prescription pre-and post-intervention as obtained from
chart abstraction.
Results of the global medication adherence analysis revealed that the
Ofﬁce-GAP program signiﬁcantly improved globalmedication adherence
from baseline to follow-up compared to control (p-value b 0.001).
Speciﬁcally, the intervention signiﬁcantly improved global medication
adherence from baseline compared to control at 3 months (OR 1.79,
95% CI = 1.06, 3.03; p-value = 0.03) and 6 months (OR 2.43, 95%
CI = 1.49; 3.97; p-value b 0.01). The difference did not reach statistical
signiﬁcance at 12months (OR 1.25, 95% CI= 0.74, 2.11; p-value b 0.41).
The analysis is adjusted for DM, HTN and the potential confounders
used in the propensity scores. Our results further revealed HTN as the
only predictor for aspirin use. However, older age, female gender and
black race predicted the use of statins. Presence of the Ofﬁce-GAP inter-
vention and HTN predicted the use of ACEI or ARBs. The Ofﬁce-GAP
intervention, older age, history of CAD, HTN and having insurance
other than the Ingham Health Plan predicted the use of beta-blockers.
Finally, global medication adherence was predicted only by the Ofﬁce-
GAP intervention and history of HTN (Table 3).Table 3
Odds Ratio [95% CI] for predictors of medication use over time.
Aspirin Statin
3 months vs baseline 1.18
[0.89, 1.55]
1.58‡
[1.16, 2.16]
6 months vs baseline 1.70‡
[1.23, 2.36]
1.74‡
[1.18, 2.56]
12 months vs baseline 1.90‡
[1.24, 2.91]
1.32
[0.83, 2.09]
GAP vs control 11.18‡
[4.63, 27.03]
1.35
[0.62, 2.94]
(Age + 1) vs age 1.00
[0.95, 1.05]
1.05⁎
[1.00, 1.10]
Female vs male 0.93
[0.45, 1.95]
2.29⁎
[1.03, 5.08]
Asian vs White 1.43
[0.45, 4.54]
1.15
[0.28, 4.66]
Black vs White 1.19
[0.49, 2.92]
3.04‡
[1.37, 6.73]
Other vs White 0.63
[0.19, 2.12]
2.17
[0.44, 10.76]
CAD vs no CAD 3.07
[0.98, 9.65]
1.83
[0.63, 5.31]
No IHP vs IHP 2.17
[0.66, 7.06]
1.06
[0.40, 2.79]
No Medicare vs Medicare 0.88
[0.31, 2.46]
1.42
[0.54, 3.66]
No Medicaid vs Medicaid 2.33
[0.88, 6.18]
1.19
[0.48, 2.91]
HTN vs no HTN 4.08‡
[1.53, 10.87]
1.58
[0.64, 3.89]
ACEI: angiotensin converting enzyme inhibitor.
ARB: angiotensin receptor blocker.
IHP: Ingham Health Plan insurance.
CAD: coronary artery disease.
HTN: hypertension.
GAP: Guidelines Applied to Practice.
Adjusted for hypertension, diabetes mellitus, and variables in the propensity score.
‡ p-Value b 0.01.
⁎ p-Value b 0.05.7. Discussion
Feasibility of the Ofﬁce-GAP program in the FQHC settings was
established. The Ofﬁce-GAP Program led to the signiﬁcantly increased
use, relative to the control, of ACEI or ARBs, statins and aspirin in pa-
tients with DM, CHD or both in this low-income population. There
was no change in the use of beta-blockers in either the intervention
and control arms. However, there was a trend toward a higher use of
beta-blockers at 3 months (47.6%), 6 months (59.5%) and 12 months
(50.0%) compared to baseline use (46.5%) in the intervention arm.Med-
ication use in the study was in accordance to AHA/ACCF and ADA
guideline-based care for secondary prevention of heart disease in pa-
tients with diabetes and CHD. The novel Ofﬁce-GAP tool was found to
be almost universally used in this study. This multi-faceted intervention
had two characteristics not frequently found in other SDM and patient
activation interventions. One is that the toolswere simple and delivered
by providers and ofﬁce staff. The second is the team-based approach;
the physician and patient interventions designed to be parallel in
Ofﬁce-GAP program supported the therapeutic partnership from both
perspectives, and put patients and providers on the same page. The pro-
gram content in the group visit included discussion of the purpose and
side effects of medications. The one-page Ofﬁce-GAP checklist provided
educational content and structures the clinical encounter. It enabled
physicians to systematically review evidence-based care options for
every patient during each encounter. This approach has been advocated
but infrequently implemented in clinical practice (Roter & Larson,
2001). Empowering patients to interact with health care providers
and promoting engagement have been described as important consid-
erations in improving uptake and adherence to medications (CarmanACEI/ARB Beta-blocker “Global” medication adherence
1.33
[0.98, 1.80]
1.60
[0.96, 2.66]
1.26
[0.96, 1.65]
1.17
[0.86, 1.60]
1.39
[0.82, 2.33]
1.15
[0.87, 1.51]
1.18
[0.82, 1.70]
0.96
[0.49, 1.86]
1.17
[0.84, 1.62]
1.92⁎
[1.03, 3.63]
0.16⁎
[0.04, 0.66]
2.34‡
[1.28, 4.30]
1.01
[0.97,1.04]
1.12‡
[1.04, 1.21]
1.00
[0.98, 1.03]
0.64
[0.33, 1.21]
0.48
[0.14, 1.58]
0.74
[0.40, 1.35]
0.61
[0.23, 1.57]
0.38
[0.06, 2.36]
0.53
[0.21, 1.30]
1.07
[0.55, 2.08]
3.85
[0.81, 18.35]
1.04
[0.55, 1.97]
2.33
[0.53, 10.24]
3.48
[0.57, 21.41]
2.02
[0.56, 7.28]
0.78
[0.33, 1.84]
11.06‡
[2.50, 48.74]
0.63
[0.28, 1.45]
1.30
[0.62, 2.73]
5.51⁎
[1.34, 22.61]
1.27 [0.63, 2.56]
0.88
[0.41, 1.89]
1.26
[0.28, 5.73]
0.83
[0.40, 1.74]
1.18
[0.57, 2.39]
1.35
[0.43, 4.30]
1.30 [0.66, 2.56]
7.38‡
[3.65, 14.93]
4.99‡
[1.51, 16.49]
5.62‡
[2.82, 11.19]
362 A. Olomu et al. / Preventive Medicine Reports 4 (2016) 357–363et al., 2013; Koh et al., 2013). A growing body of evidence suggests that
patient engagement can lead to better health outcomes, contributes to
improvement in quality and patient safety (Coulter & Ellins, 2007),
and helps control healthcare costs (Charmel & Frampton, 2008).
Previous studies have rarely shown an impact of communication skills
interventions on patient behavior (Dwamena et al., 2012). Our results,
however, are consistent with the ﬁndings of Cooper et al. (2011) who
showed that the greatest improvements in BP control were seen
among patients who received coaching by community health workers
and among thosewhose physicians also received patient-centered com-
munication skill training. We showed improved physician prescribing
behavior and patient follow-through. Based on prior research in second-
ary prevention, it should be expected that sustained improvement in
medication use and lifestyle will lead to improved cardiovascular
outcomes (Eagle et al., 2005). The importance of guideline adherence
is underscored by the mortality beneﬁt that can be achieved by partici-
pants in these programs (Eagle et al., 2005). We studied minority and
low-income populations who are unlikely to be able to afford the cost
of medications without insurance coverage. Availability of insurance
coverage in Medicaid Expansion states under the Affordable Care Act
should improve and sustain access to these medications.
Our study has certain limitations. Ofﬁce-GAP implementation was
tested in two small cohorts at FQHCs andnot in a randomized controlled
trial, limiting the generalizability of our ﬁndings to other health care set-
tings. The educational intervention exposure for physicians was limited
to a one-time administration, and may degrade over time. However,
Ofﬁce-GAP tools reinforced SDM in the follow-up interactions. Since
this is an integrated model, we are unable to disentangle the effects of
the provider training and the patient training to explain our results.
The increase in medication use may reﬂect more effective physician
prescribing and communication practices, as well as more effective
patient communication and activation. The study has several strengths.
We believe that the Ofﬁce-GAP initiative may provide the foundation
for future initiatives and that it is unique in several ways. First, the
tools reminded physicians, nurses and patients of the key goals of ther-
apy in real time and in follow-up ofﬁce visits. Ofﬁce-GAP strengthened
SDM and resulted in improved medication use in an underserved
population not characterized by high engagement at baseline. Second,
the tools' design was very simple and easy to use at the point of care.
Third, all the physicians and practice staff were involved in the training
and implementation of the tools and assisted in identifying the barriers
to successful implementation, a strategy previously proven to be
effective in inﬂuencing physician behavior.
8. Conclusion
Feasibility of the Ofﬁce-GAP program in the FQHC setting was
established. This physician-patient engagement program led to
increased use of guideline-based medications for secondary CHD
prevention in underserved populations. The Ofﬁce-GAP program is a
brief, efﬁcient platform for delivering patient and provider education
in SDM and could serve as a model for implementing guideline-based
care for other chronic diseases in outpatient settings. Further study is
needed to establish reach, effectiveness, and cost-effectiveness of physi-
cian and patient interventions designed in tandem for underserved
populations.
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